Free Trial
OTCMKTS:IPHYF

Innate Pharma (IPHYF) Stock Price, News & Analysis

Innate Pharma logo
$2.90 0.00 (0.00%)
As of 04/2/2025

About Innate Pharma Stock (OTCMKTS:IPHYF)

Key Stats

Today's Range
$2.90
$2.90
50-Day Range
$2.90
$2.90
52-Week Range
$1.28
$2.90
Volume
N/A
Average Volume
N/A
Market Capitalization
$232.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Remove Ads
Receive IPHYF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter.

IPHYF Stock News Headlines

This almost killed Elon Musk (chilling details emerge)
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a terrifying supercar crash with billionaire Peter Thiel, then from a deadly strain of malaria—Elon Musk emerged with a stark warning for Americans about looming financial dangers. Discover the little-known Trump IRS loophole that thousands are now using to safeguard their retirement from inflation and market turmoil—before it's too late.
3 Promising Penny Stocks With Market Caps Under US$500M
Evercore ISI Sticks to Its Buy Rating for Innate Pharma (IPHA)
See More Headlines

IPHYF Stock Analysis - Frequently Asked Questions

Innate Pharma's stock was trading at $2.90 at the beginning of 2025. Since then, IPHYF shares have increased by 0.0% and is now trading at $2.90.
View the best growth stocks for 2025 here
.

Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/03/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
OTCMKTS:IPHYF
Previous Symbol
NASDAQ:IPHYF
Employees
179
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$66.71 million
Price / Cash Flow
N/A
Book Value
$0.70 per share
Price / Book
4.14

Miscellaneous

Free Float
57,097,000
Market Cap
$232.61 million
Optionable
Not Optionable
Beta
1.07
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:IPHYF) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners